BridgeBio Pharma Inc (BBIO) Reports Q4 and Full Year 2023 Financials, Advances Key Clinical Trials [Yahoo! Finance]
BridgeBio Pharma, Inc. (BBIO)
Last bridgebio pharma, inc. earnings: 3/2 08:29 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Operating Costs and Expenses : Increased to $616.7 million for the full year 2023, up from $589.9 million in the previous year. Net Loss : Grew to $(653.3) million for the full year 2023, compared to $(484.7) million in the previous year. Cash Position : Ended the year with $393 million in cash, cash equivalents, and short-term restricted cash. Strategic Capital : Secured up to $1.25 billion from Blue Owl and CPP investments, enhancing financial flexibility. Clinical Advancements : Progressed with key clinical trials, including the Phase 3 study of infigratinib for achondroplasia and the Phase 3 study of BBP-418 for LGMD2I. Warning! GuruFocus has detected 5 Warning Signs with BBIO. On February 22, 2024, BridgeBio Pharma Inc ( NASDAQ:BBIO ) released its 8-K filing , detailing the financial results for the fourth quarter and full year ended December 31, 2023, and providing a business update. The company, which focuses on genetic diseases and cancers, has made significant st
Show less
Read more
Impact Snapshot
Event Time:
BBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BBIO alerts
High impacting BridgeBio Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
BBIO
News
- BridgeBio Pharma First Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
- BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business UpdateGlobeNewswire
- BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline [Yahoo! Finance]Yahoo! Finance
- BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipelineGlobeNewswire
- Sentynl Therapeutics Receives MHRA Authorization of NULIBRY® (fosdenopterin) for Treatment of MoCD Type A in Great Britain [Yahoo! Finance]Yahoo! Finance
BBIO
Earnings
- 5/2/24 - Beat
BBIO
Sec Filings
- 5/2/24 - Form 10-Q
- 5/2/24 - Form 8-K
- 4/25/24 - Form ARS
- BBIO's page on the SEC website